Genmab axes three antibody programs amid pipeline reprioritization

8 November 2024

Genmab (Nasdaq: GMAB) announced during its third-quarter earnings call on Wednesday that it has discontinued three antibody programs as part of a pipeline overhaul.

Designed to refocus its resources, the shake-up will affect the development of GEN1047, GEN3017 and GEN1056, which were at various stages of progress.

GEN1047 is a CD3/B7H4 bispecific antibody in Phase I/II trials for solid tumors, while GEN3017 is a CD3/CD30 bispecific targeting Hodgkin lymphoma and non-Hodgkin lymphoma, currently in Phase I trials. GEN1056 is another Phase I asset, an antibody being evaluated in partnership with BioNTech (Nasdaq: BNTX) for solid tumors.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK